Metabolic and functional relevance of HDL subspecies

Current Opinion in Lipidology

Volumn 22, Issue 3, 2011, Pages 176-185

  Asztalos, Bela F ^a   Tani, Mariko ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

dysfunctional HDL; HDL; HDL function; HDL metabolism; HDL structure; HDL subclass

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

APOPTOSIS; ARTICLE; CHOLESTEROL TRANSPORT; GAS CHROMATOGRAPHY; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID METABOLISM; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; APOLIPOPROTEINS; ATHEROSCLEROSIS; CHOLESTEROL; COMPLEMENT SYSTEM PROTEINS; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; PARTICLE SIZE; TERMINOLOGY AS TOPIC;

EID: 79957882578     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283468061     Document Type: Article

References (96)

1. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res 1984; 25:1017-1058.
2. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardi-ovascular events. Clin Chem 2011; 57:392-410.
3. Asztalos BF, Roheim PS, Milani RL, et al. Distribution of apoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 2000; 20:2670-2676.
4. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha-1 HDL concen-tration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003; 23:847-852. (Pubitemid 36566176)
5. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein sub-population profile and heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004; 24:2181-2187. (Pubitemid 39482449)
6. Asztalos BF, Collins D, Cupples LA, et al. Value of HDL subpopulations in predicting recurrent cardiovascular events in the VA-HIT. Arterioscler Thromb Vasc Biol 2005; 25:2185-2191.
7. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
8. Miida T, Nakamura Y, Inano K, et al. Prebeta-1 high-density lipoprotein increases in coronary artery disease. Clin Chem 1996; 42:1992-1995. (Pubitemid 26415351)
9. Sethi AA, Sampson M, Warnick R, et al. High prebeta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem 2010; 56:1128-1137.
10. Sacks FM, Rudel LL, Connor A, et al. Selective delipidation of plasma HDL enhances reversecholesterol transport in vivo. J Lipid Res 2009;50:894-907.
11. Waksman R,Torguson R, Kent KM, et al. Afirst-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010; 55:2727-2735.
12. Asztalos BF, Schaefer EJ, Horvath KV, et al. Roleof LCATin HDLremodeling: investigation of LCAT deficiency states. J Lipid Res 2007; 48:592-599. (Pubitemid 46397462)
13. Tian L, Fu M. The relationship between high density lipoprotein subclass profile and plasma lipids concentrations. Lipids Health Dis 2010; 9:118.
14. Asztalos BF,SwarbrickMM,Schaefer EJ, et al. Effectsof weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res 2010; 51:2405-2412.
15. Shuhei N, Söderlund S, Jauhiainen M, et al. Effect of HDL composition and particle size on the resistance of HDLtothe oxidation. Lipids Health Dis 2010; 9:104.
16. Bergmeier C, Siekmeier R, Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin Chem 2004; 12:2309-2315. (Pubitemid 39552166)
17. Hara T, Ishida T, Kojima Y, et al. Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J Lipid Res 2011; 52:57-67.
18. Brown RJ, Lagor WR, Sankaranaravanan S, et al. Impact of combined deficiency of hepatic lipase and endothelial lipase on the metabolism of both high-density lipoproteins and apolipoprotein B-containing lipoproteins. Circ Res 2010; 107:357-364.
19. Vergeer M, Cohn DM, Boekholdt SM, et al. Lack of association between common genetic variation in endothelial lipase (LIPG) and the risk for CAD and DVT. Atherosclerosis 2010; 211:558-564.
20. Vergeer M, Korporaal SJ, Franssen R, et al. Genetic variant of the scavenger receptor BI in humans. N Engl J Med 2011; 364:136-145.
21. Vergeer M, Boekholdt SM, Sandhu MS, et al. Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipo-protein size and is a novel marker of cardiovascular disease susceptibility. Circulation 2010; 122:470-477.
22. Lee MH, Hammad SM, Semler AJ, et al. HDL3, but not HDL2, stimulates plasminogen activator inhibitor-1 release from adipocytes: the role of sphin-gosine-1-phosphate. J Lipid Res 2010; 51:2619-2628.
23. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82:201-211.
24. De Souza JA, Vindis C, Nègre-Salvayre A, et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2010; 14:608-620.
25. Mora S, Otvos JD, Rosenson RS, et al. Lipoprotein particle size and con-centration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes 2010; 59:1153-1160.
26. Lee M, Jang Y, Kim K, et al. Relationship between HDL3 subclassesand waist circumferences on the prevalence of metabolic syndrome: KMSRI-Seoul Study. Atherosclerosis 2010; 213:288-293.
27. Hodge AM, Jenkins AJ, English DR, et al. NMR-determined lipoprotein subclass profile is associated with dietary composition and body size. Nutr Metab Cardiovasc Dis 2010. [Epub ahead of print]
28. Ridker PM, Genest J, Boekholdt SM, et al. JUPITER Trial Study Group. HDL cholesterol and residual riskof first cardiovascularevents aftertreatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010; 376:333-339.
29. Drexel H, Aczel S, Marte T, et al. Factors predicting cardiovascular events in statin-treated diabetic and nondiabetic patients with coronary atherosclerosis. Atherosclerosis 2010; 208:484-489.
30. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297: 499-508. (Pubitemid 46220805)
31. Felix-Getzik EM, Kuvin JT, Karas RH. Nonoptimal high-density lipoprotein cholesterol levels are highly prevalent in patients presenting with acute coronary syndromes and well controlled low-density lipoprotein cholesterol levels. J Clin Lipidol 2010; 4:265-271.
32. Saely CH, Vonbank A, Drexel H. HDL cholesterol and residual risk of first cardiovascular events. Lancet 2010; 376:1738; author reply 1738-1739.
33. Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V, et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010; 210:548-554.
34. Gauthamadasa K, Rosales C, Pownall HJ, et al. Speciated human high-density lipoprotein protein proximity profiles. Biochemistry 2010; 49: 10656-10665.
35. Jonas A. Lipoprotein structure. In: Vance DE and Vance JE, editors. Biochem-istry of lipids, lipoproteins and membranes. Amsterdam: Elsevier Science; 2002. pp. 483-504.
36. Gordon SM, Deng J, Lu LJ, et al. Proteomiccharacterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010; 9:5239-5249.
37. Davidson WS, Silva RA, Chantepie S, et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009; 29:870-876.
38. Asztalos BF, Horvath KV, Kajinami K, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004; 45:448-455. (Pubitemid 38337991)
39. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory proper-ties of HDL J Clin Invest 2007; 117:746-756. (Pubitemid 46348533)
40. Asztalos BF. High density lipoprotein particles. In: Schaefer EJ, editor. High density lipoproteins, dyslipidemia, and coronary heart disease. Berlin: Spin-ger; 2011.
41. Asztalos BF, Brousseau ME, McNamara JR, et al. Subpopulations of high density lipoproteins in homozygous and heterozygous Tangier disease. Atherosclerosis 2001; 156:217-225. (Pubitemid 32429615)
42. Santos RD, Schaefer EJ, Asztalos BF, et al. Characterization of high density lipoprotein particles infamilial apolipoprotein A-I deficiency. J Lipid Res 2008; 49:349-357. (Pubitemid 351213619)
43. De la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
44. Brown MS, Ye J, Goldstein JL Medicine. HDL miR-ed down by SREBP introns. Science 2010; 328:1495-1496.
45. Najafi-Shoushtari SH, Kristo F, Li Y, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-1569.
46. Rayner KJ, Suarez Y, DavalosA, et al. miR-33 contributesto the regulation of homeostasis. Science 2010; 328:1570-1573.
47. Horie T, Ono K, Horiguchi M, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010; 107:17321-17326.
48. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010; 107:12228-12232.
49. Gerin I, Cler baux LA, Haumont O, et al. Expression of miR-33 from the SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010; 285:33652-33661.
50. Ho PC, Chang KC, Chuang YS, Wei LN. Cholesterol regulation of receptor-interacting protein 140via microRNA-33 in inflammatory cytokine production. FASEB J 2011. [Epub ahead of print]
51. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005; 96:1221-1232. (Pubitemid 40962099)
52. Cuchel M, Rader DJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation 2006; 113:2548-2555. (Pubitemid 43948034)
53. Getz GS, Reardon CA. High-density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. Arterioscler Thromb Vasc Biol 2010; 30:1497-1499.
54. Fryirs MA, Barter PJ, Appavoo M, et al. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010; 30:1642-1648.
55. Rütti S, Ehses JA, Sibler RA, et al. Low-and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells. Endocrinology 2009; 150:4521-4530.
56. Van LinthoutS, Foryst-Ludwig A,Spillmann F, et al. Impactof HDLon adipose tissue metabolism and adiponectin expression. Atherosclerosis 2010; 210: 438-444.
57. Luo N, Liu J, Chung BH, et al. Macrophage adiponectin expression improves insulin sensitivity and protects against inflammation and atherosclerosis. Diabetes 2010; 59:791-799.
58. Iwabu M, Yamauchi T, Okada-Iwabu M, et al. Adiponectin and adipoR1 regulate PGC-1α and mitochondria by Ca2+ and AMPK/SIRT1. Nature 2010; 464:1313-1319.
59. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apop-tosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 2007; 104:15093-15098. (Pubitemid 47619598)
60. Cui D, Thorp E, Li Y, et al. Pivotal advance: macrophages become resistant to cholesterol-induced death after phagocytosis of apoptoticcells. J Leukoc Biol 2007; 82:1040-1050. (Pubitemid 350133499)
61. Cockerill GW, Rye KA, Gamble JR, et al. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arter-ioscler Thromb Vasc Biol 1995; 15:1987-1994.
62. Terasaka N, Westerterp M, Koetsveld J, et al. ATP-binding cassette trans-porter G1 and high-density lipoprotein promote endothelial NO synthesis through a decrease in the interaction of caveolin-1 and endothelial NO synthase. Arterioscler Thromb Vasc Biol 2010; 30:2219-2225.
63. Navab M, Berliner JA, Subbanagounder G, et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001; 4:481-488. (Pubitemid 32323377)
64. Lee CM, Chien CT, Chang PY, et al. High-density lipoprotein antagonizes oxidized low-density lipoprotein by suppressing oxygen free-radical formation and preserving nitric oxide bioactivity. Atherosclerosis 2005; 183:251-258.
65. Robbesyn F, Garcia V, Auge N, et al. HDL counterbalance the proinflamma-tory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003; 17:743-755.
66. Sorrentino SA, Besler C, Rohrer L, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010; 121:110-122.
67. Hla T, Lee MJ, Ancellin N, et al. Lysophospholipids: receptor revelations. Science 2001; 294:1875-1878.
68. Zhang Q, Yin H, Liu P, et al. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. Exp Biol Med (Maywood) 2010; 235:1082-1092.
69. Kimura T, Sato K, Kuwabara A, et al. Sphingosine-1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 2001; 276: 31780-31785.
70. Kimura T, Sato K, Malchinkhuu E, et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine-1- phosphate and its receptors. Arterioscle Thromb Vasc Biol 2003; 23:1283-1288. (Pubitemid 36871285)
71. Lucke S, Levkau B. Endothelial functions of sphingosine-1-phosphate. Cell Physiol Biochem 2010; 26:87-96.
72. Ahotupa M, Suomela JP, Vuorimaa T, Vasankari T. Lipoprotein-specific transport of circulating lipid peroxides. Ann Med 2010; 42:521-529.
73. Ansell BJ, Navab M, Hama S, et al. Inflammatory-anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment Circulation 2003; 108:2751-2756. (Pubitemid 37498976)
74. Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses thetype I interferon response, afamily of potentantiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010; 122: 1919-1927.
75. Henning MF, Herlax V, Bakas L. Contribution on the C-terminal end of apolipoprotein A-I to neutralization of lipopolysaccharide endotoxic effect. Innate Immun 2011. [Epub ahead of print]
76. Thomson R, Samanovic M, Raper J. Activity of trypanosoma lytic factor: a novel component of innate immunity. Future Microbiol 2009; 7:789-796.
77. Feingold KR, Grunfeld C The role of HDL in innate immunity. J Lipid Res 2011; 52:1-3.
78. Acuña-Alonzo V, Flores-Dorantes T, Kruit JK, et al. A functional ABCA1 gene variant is associated with low HDL-cholesterol levels and shows evidence of positive selection in Native Americans. Hum Mol Genet 2010; 19:2877-2885.
79. Eggesbo JB, Lyberg T, Aspelin T, et al. Different binding of 125I-LPS to plasma proteins from persons with high or low HDL Scand J Clin Lab Invest 1996; 56:533-543. (Pubitemid 26342638)
80. Tang C, Kanter JE, Bornfeldt KE, et al. Diabetes reduces the cholesterol exporter ABCA1 in mouse macrophages and kidneys. J Lipid Res 2010; 51:1719-1728.
81. Vergeer M, Brunham LR, Koetsveld J, et al. Carriers of loss-of-function mutations in ABCA1 display pancreatic beta-cell dysfunction. Diabetes Care 2010; 33:869-874.
82. Nobecourt E, Jacqueminet S, Hansel B, et al. Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycemia. Diabetologia 2005; 48:529-538. (Pubitemid 40487300)
83. Shao B, Pennathur S, Pagani I, et al. Modifying apolipoprotein A-I by malondialdehyde, but not by an array of other reactive carbonyls, blocks cholesterol efflux bytheABCA1 pathway. J Biol Chem 2010; 285:18473-18484.
84. Hildebrand RB, Lammers B, Meurs I, et al. Restoration of high-density lipoprotein levels by cholesteryl estertransferprotein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency. Arterioscler Thromb Vasc Biol 2010; 30:1439-1445.
85. Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol 2010; 106:757-763.
86. Tian L, Xu Y, Fu M, et al.The impactof plasmatriglycerideand apolipoproteins concentrations on high-density lipoprotein subclasses distribution. Lipids Health Dis 2011; 10:17.
87. Asztalos BF, Horvath KV, McNamara JR, et al. Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. J Lipid Res 2002; 107:387-392.
88. Asztalos BF, Collins D, Horvath KV, et al. Relation of gemfibrozil treatmentand high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 2008; 57:77-83. (Pubitemid 350234976)
89. Cavigiolio G, Geier EG, Shao B, et al. Exchangeof apolipoprotein A-I between lipid-associated and lipid-free states: a potential target for oxidative generation of dysfunctional high density lipoproteins. J Biol Chem 2010; 285:18847-18857.
90. Shao B, Tang C, Heinecke JW, Oram JF. Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 2010; 51:1849-1858.
91. Shao B, Oda MN, Oram JF, Heinecke JW. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23:447-454.
92. UndurtiA, Huang Y, LupicaJA, et al. Modification of highdensity lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009; 284:30825-30835.
93. Bancells C, Sánchez-Quesada JL, Birkelund R, et al. exchange anti and pro-inflammatory properties. J Lipid Res 2010; 51:2947-2956.
94. Annema W, Nijstad N, Tölle M, et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 2010; 51:743-754.
95. Hoofnagle AN, Wu M, Gosmanova AK, et al. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipopro-teinemia. Arterioscler Thromb Vasc Biol 2010; 30:2528-2534.
96. Skaggs BJ, Hahn BH, Sahakian L, et al. Dysfunctional, pro-inflammatory HDL directly upregulates monocyte PDGFRß, chemotaxis and TNFα production. Clin Immunol 2010; 137:147-156.